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ABSTRACT Mucosal surfaces of the reproductive
tract as well as their secretions have important roles in
preventing sexual transmission of HIV-1. In the current
study, the majority of the intrinsic anti-HIV-1 activity of
human seminal plasma (SP) was determined to reside
in the cationic polypeptide fraction. Antiviral assays
utilizing luciferase reporter cells and lymphocytic cells
revealed the ability of whole SP to prevent HIV-1
infection, even when SP was diluted 3200-fold. Subse-
quent fractionation by continuous flow acid-urea (AU)-
PAGE and antiviral testing revealed that cationic
polypeptides within SP were responsible for the major-
ity of anti-HIV-1 activity. A proteomic approach was
utilized to resolve and identify 52 individual cationic
polypeptides that contribute to the aggregate anti-HIV-1
activity of SP. One peptide fragment of semenogelin I,
termed SG-1, was purified from SP by a multistep chro-
matographic approach, protein sequenced, and deter-
mined to exhibit anti-HIV-1 activity against HIV-1. Anti-
HIV-1 activity was transient, as whole SP incubated for
prolonged time intervals exhibited a proportional de-
crease in anti-HIV-1 activity that was directly attributed to
the degradation of semenogelin I peptides. Collectively,
these results indicate that the cationic polypeptide
fraction of SP is active against HIV-1, and that semeno-
gelin-derived peptides contribute to the intrinsic anti-
HIV-1 activity of SP.—Martellini, J. A., Cole, A. C.,
Venkataraman, N., Quinn, G. A., Svoboda, P., Gan-
grade, B. K., Pohl, J., Sørensen, O. E., Cole, A. M.
Cationic polypeptides contribute to the anti-HIV-1 ac-
tivity of human seminal plasma. FASEB J. 23,
3609–3618 (2009). www.fasebj.org
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HIV has become a pandemic over the past few de-
cades, newly infecting an estimated 2.7 million people
in 2007 alone. Due to the rapid mutation rate of HIV-1,
and unforeseen problems in the clinic, vaccine devel-
opment has gained insignificant headway over viral
spread. Even in the absence of preventive measures,
natural mucosal host defenses are thought to play a role
in preventing or suppressing HIV-1 transmission. Prin-
cipal molecular effectors of mucosal host defense in-
clude antimicrobial polypeptides, which exhibit a
broad range of actions against gram-negative and gram-
positive bacteria, fungi, and viruses (1–3). Mucosal
tissues throughout the human body elaborate a num-
ber of antimicrobial polypeptides that, once released
into the overlying fluid, quickly and effectively eradi-
cate invading pathogens. While biological evidence for
antibacterial and antifungal host defense has been
established (4), only a comparably few studies have
focused on the antiviral activities and mechanisms of
these polypeptides (5).
The main antimicrobial peptides and proteins found
on mucosal surfaces are cationic in nature and include
lysozyme, secretory leukocyte protease inhibitor (SLPI),
lactoferrin, defensins, and the cathelicidin LL-37. Alone
they exhibit only modest antiviral activity against HIV-1,
yet in concert with other peptides (e.g., example in
human vaginal fluid), they can exert significant anti-
HIV-1 activity (6). While human seminal plasma (SP)
contains several antimicrobial polypeptides, including
hCAP18, the precursor protein of LL-37, and defensins
(7, 8), a number of other cationic polypeptides and
their roles in antiviral host defense have not yet been
studied. The most abundant proteins in SP are semeno-
gelin I and semenogelin II, secreted from the seminal
vesicles. These proteins immediately form a nonco-
valently linked coagulum, which is subsequently lique-
fied by proteases that hydrolyze the gel proteins into
soluble fragments (7, 9–11). Studies have reported
antibacterial activity of semenogelin-derived peptides
(12, 13), which our group has recently confirmed and
extended (14).
While studies have determined the antibacterial ef-
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fects of individual cationic polypeptides found in SP,
the antiviral activity of the cationic component of SP
has not been investigated. Moreover, histidine-rich
peptides have not been reported to play a major role in
anti-HIV-1 host defense. In the current study, the
anti-HIV-1 activity of SP was found to be contained in
the cationic polypeptide fraction, revealing a significant
host defense function against HIV-1. Further, electro-
phoretic and chromatographic fractionation followed
by proteomic analyses identified 52 separate cationic
polypeptides, many of which contributed to the aggre-
gate anti-HIV-1 activity of SP. Notably, a recent study
reported semen-mediated enhancement of HIV trans-
mission, due to prostatic acid phosphatase (PAP)-de-
rived amyloid fibrils (15). While certain methods differ
between this report and our current study, taken to-
gether, it is clear that both proviral and antiviral factors
are present within SP. Our results provide biological
evidence that SP is naturally antiviral against HIV-1,
suggesting an innate defense mechanism that prevents
HIV-1 transmission.
MATERIALS AND METHODS
Collection and processing of human SP
Samples of human semen were collected by the Center for
Reproductive Medicine (Orlando, FL, USA) for routine sem-
inal analyses, and the discarded deidentified SP component
was used for this study. Patients were asked to refrain from
ejaculation for 2–3 d, but no more than 5 d, prior to
collection, and semen was obtained using dry masturbation
into a sterile polypropylene cup. All samples were allowed to
liquefy for 30 min at room temperature and centrifuged for
30 min at 1500 g in order to remove any cellular debris. A
total of 103 SP samples were collected, with volumes ranging
from 0.5 to 6 ml, and equal volumes of all donor samples were
pooled, portioned into aliquots, and stored at 80°C until
needed. The average protein concentration of SP was ac-
quired using a Micro BCA Protein Assay (Pierce, Rockford,
IL, USA) using diluted bovine serum albumin (BSA) as a
standard. The assay was repeated 3 times in triplicate, reveal-
ing an average protein concentration of 161.3 mg/ml. Average
pH of whole undiluted SP was determined with colorpHast pH
indicator strips (EMD Chemicals Inc., Gibbstown, NJ, USA) and
observed at a pH of 7.75 (n3). Whole SP utilized for antiviral
cell culture assays was not manipulated further.
Cell lines and viruses
The TZM-bl and PM1 cell lines were obtained from the
National Institutes of Health (NIH) AIDS Research and
Reference Reagent Program (Germantown, MD, USA).
TZM-bl cells are a stable line of HeLa-derived epithelia.
They contain Tat-regulated reporter genes, and neutralize
virus after single-round infections. When used with Env-
pseudotyped laboratory strains of HIV, TZM-bl cells can
undergo a luciferase (Luc) reporter gene assay that performs
a sensitive and rapid report of the extent of viral infection.
TZM-bl cells were grown in D10 medium: high-glucose
DMEM (Mediatech, Manassas, VA, USA) supplemented with
100 U/ml penicillin, 100 g/ml streptomycin, and 10% (v/v)
fetal bovine serum. PM1 cell cultures were maintained at a
density of 0.4–0.8 106 cells/ml in R20 medium: RPMI 1640
supplemented with 100 U/ml penicillin, 100 g/ml strepto-
mycin, 100 mM HEPES, and 20% (v/v) fetal bovine serum
(Gemini Bio-Products, West Sacramento, CA, USA). The
HIV-1 strain BaL (R5) was obtained from the NIH AIDS
Research and Reference Reagent Program. HIV-1 BaL was
propagated in PM1 cells over 16 d, and virus-containing
supernatant was collected every other day starting on d 5 of
infection. Supernatant was filtered through a 0.45-m pore-
size filter and stored in 0.5- or 1-ml aliquots at 80°C until
needed. Viral quantification was achieved via a sensitive
commercial ELISA for p24gag (PerkinElmer, Waltham, MA,
USA).
Experimental determination of anti-HIV-1 activity and
cytotoxic effects
For antiviral experiments with whole SP, fractionated SP, and
synthetic and purified cationic peptide fragments of semeno-
gelin I, which we termed SG-1, Tzm-bl cells were trypsinized,
counted via hemocytometer, and seeded to 6  104 cells/ml
(6000 cells/well) in a 96-well microtiter plate. After 24 h, cells
were treated in triplicate with 50 l of D10 containing
treatment sample. Immediately following treatment, 50 l of
virus diluted to a constant final concentration (5 ng p24/ml)
in D10 was added to each well and incubated at 37°C in 5%
CO2. After a 24-h infection period, cells were lysed using a
Bright Glo luciferase system (Promega, Madison, WI, USA),
and luciferase was quantified with a Spectramax luminometer
(Molecular Devices Corp., Sunnyvale, CA, USA), with an
integration time of 5 s/well (16). Ability to prevent HIV-1
infection was measured as a percentage reduction in lucif-
erase (relative light units) compared to the positive viral
control (medium and virus only), while the negative control
(medium only, no virus) acted as the baseline comparison.
Metabolic activity and cytotoxicity of the cells were verified by
a tetrazolium-based [3-(4,5-dimethyl-2-thizolyl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT)] assay according to the man-
ufacturer’s instructions (R&D Systems, Minneapolis, MN,
USA) and a standard trypan blue dye-exclusion assay (17),
performed in parallel with the HIV-treated cells.
PM1 cells (1.5105/0.1 ml) were treated with whole SP
diluted in R20, infected with HIV-1 BaL (2 ng p24/ml), and
incubated for 3 h at 37°C in 5% CO2 with agitation of the cell
suspension every 30 min. The cell suspension was then
diluted with 2 ml of R20; pelleted; resuspended in 0.5 ml of
diluted whole SP in R20 medium, or vehicle only; and
incubated at 37°C in 5% CO2. At 3 d postinfection, the
supernatants were collected and stored at 20°C, and the
remaining cells in culture were resuspended in 0.5 ml of
diluted whole SP or R20 alone. On d 5, supernatants were
collected and stored, and a trypan blue dye assay was per-
formed on the cells, as described previously. To quantify the
viral inhibition of SP, d 5 supernatants underwent an ELISA
for p24gag (PerkinElmer) and were compared to vehicle-only
control.
Resolution of SP via 2-dimensional polyacrylamide gel
electrophoresis (2-D PAGE)
Whole SP was electrophoresed on a 2-D acid-urea (AU)/
tricine-SDS-PAGE as described previously (6). Briefly, SP was
prepared in a 1:1 ratio with 0.2% cetyltrimethyl ammonium
bromide (CETAB) and then admixed 1:1 with 3 AU loading
dye (9 M urea, 5% acetic acid, and methyl green). A 12.5%
native AU-PAGE was used as the first dimension to separate
peptides based on their overall cationic charge density. The
gel was electrophoresed at 65 V for 20–22 h and stained with
10% (v/v) amido black, and each lane was excised and
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prepared for the second dimension by soaking in equilibrium
buffer containing 10 mg/ml DTT. Gel strips were inserted
horizontally and electrophoresed on a 16% tricine-SDS-PAGE
(second dimension) at 35 mA, for 27–29 h. Individual protein
spots were visualized using Sypro Ruby gel stain (Bio-Rad,
Hercules, CA, USA), excised from the gel, and stored in
0.01% acetic acid at 20°C until analyzed by mass spectrom-
etry.
Identification of individual cationic components
in human SP
Excised 2-D PAGE spots underwent trypsin digestion and
mass spectrometric (MALDI-TOF/TOF MS/MS) analyses as
described previously (6). The resulting digested peptide
fragments were identified utilizing GPS Explorer 2.0 software
(Applied Biosystems, Foster City, CA, USA) and a Mascot
(http://www.matrixscience.com) search engine. The NCBInr
database (National Center for Biotechnology Information,
Bethesda, MD, USA) and Homo sapiens taxonomy were used
for the searches.
Fractionation of SP based on charge density
Whole SP was prepared for fractionation by adding 3 AU
loading dye (1:2 with 70 l SP-1). The Miniprep Cell Frac-
tionation and Continuous-Elution Electrophoresis System
(Bio-Rad) with a 12.5% AU-PAGE column gel was utilized to
collect larger amounts of cationic polypeptides. Elution
buffer was 5% acetic acid using an isocratic gradient collect-
ing at 0.1 ml/min. The column gel was electrophoresed at 70
V overnight, and fractions were collected every 15 min (1.5
ml/fraction). Fractions (40) were collected for each run and
either processed for purification immediately or stored at 4°C
overnight.
Processing of fractionated SP
Fractions collected from the AU-PAGE column gel were dried
under vacuum (Speedvac; ThermoSavant, Holbrook, NY,
USA) with no heat. Fractions were then resuspended in
high-pressure liquid chromatography (HPLC)-grade H2O
and electrophoresed in order of elution (fractions 1–40) on
mini-16% tricine-SDS gels (4 l sample  5 l Laemli buffer 
3 l SDS-loading buffer). These single-dimension electro-
pherograms were compared with the 2-D PAGE gels to
identify bands.
Fractions 1–40 then underwent solid-phase extraction to
desalt and concentrate each sample in preparation for cell
culture. Sep-Pak C18 polypropylene syringe-barrel cartridges
(1 cc, 50 mg; Waters Corp., Milford, MA, USA) were used
according to the manufacturer’s instructions. Cartridges were
preconditioned with ddH2O/0.1% trifluoroacetic acid (TFA)
and eluted at a rate of 0.25 ml/min. To ensure maximum
binding, the flow-through was reapplied to the column bed 3
times, washed with ddH2O/0.1% TFA, and eluted with 60%
acetonitrile (ACN) in HPLC-grade H2O, followed by 100%
methanol. All elutions were collected, dried under vacuum,
and resuspended in HPLC-grade H2O. Mini-16% tricine-SDS
gels were used to confirm that the protein banding patterns
were identical to those of predesalted fractions.
Purification of SG-1 utilizing reverse-phase (RP)-HPLC
Fractions 5–9 (of 40) containing the cationic peptide frag-
ment of semenogelin I that we termed SG-1 were pooled and
subjected to RP-HPLC. For RP-HPLC, a Waters 2795 separa-
tion module and dual-wavelength absorbance detector with a
Waters XTerra analytical column (silica, C18, 4.6250 mm,
5.0-m particle size) were used. The aqueous mobile phase
used was HPLC-grade H2O with 0.1% TFA, against a 1-ml/
min gradient from 0–60% ACN/0.08%TFA. Peak fractions
(280-nm absorbance) were vacuum-dried and resuspended in
0.1% TFA and HPLC-grade H2O. All fractions containing the
semipurified peptide were pooled together and were sub-
jected to microbore RP-HPLC (silica C18, 1.0150 mm,
3.5-m bead size, XTerra column; Waters Corp.) under a
similar ACN gradient. Eluted fractions corresponding to the
specific SG-1 peak on the chromatogram were vacuum-dried
and resuspended in HPLC-grade H2O. A Micro BCA Protein
Assay (Pierce), using diluted BSA as a standard, was per-
formed to quantify the concentration of purified SG-1 in the
pooled sample. Purified SG-1 was analyzed by MALDI-
TOF-MS and N-terminal Edman degradation to determine
the exact mass of the polypeptide sequence.
Semenogelin-specific Western blot analysis
Samples were electrophoresed in either 16% mini-tricine-SDS
gels or 12.5% mini-AU gels, as described previously (18, 19).
Gels were either stained with Sypro Ruby gel stain (Bio-Rad)
or transferred onto an Immobilon-P membrane (Millipore,
Billerica, MA, USA) activated with methanol and Tris-buff-
ered saline (TBS) at 180 mA for 45 min using the Mighty
Small Transphor vertical electrophoresis system (Amersham
Biosciences, Piscataway, NJ, USA). Membranes were fixed
with 0.05% glutaraldehyde in TBS for 20 min, and blocked
for 30 min at 37°C with Superblock (Pierce). Membranes
were incubated overnight with a mouse polyclonal anti-
semenogelin I (SGI) antibody (Novus Biologicals, Littleton,
CO, USA), immunoreactive against the full-length human
protein, diluted 1:1000 in antibody buffer (Superblock in
TBS0.05% Tween-20). Once washed, blocked at 37°C for 15
min, and incubated with peroxidase-conjugated anti-mouse
immunoglobulin-G for 2 h, the membranes were again
washed and developed using the Immun-Star HRP (Bio-Rad).
Membranes were imaged and analyzed using ChemiDoc XRS
with Quantity One software (Bio-Rad).
Statistical analyses
The antiviral and cytotoxicity assays were performed in trip-
licate for each treatment of each experimental condition. For
the TZM-bl antiviral assays, luciferase was measured as relative
light units (RLU), and the infected vehicle-only controls were
set as 100% infection. For the PM1 antiviral assays, p24 ELISA
quantification established the infected, vehicle-only control as
100% infection. Metabolic and cytotoxicity assays compared
results to the untreated, vehicle-only control, calculating
variations as a percentage of the baseline. Individual treat-
ments were analyzed by either 1-way ANOVA with Tukey’s
multiple posttest comparisons, or 2-tailed unpaired t test.
Mass spectrometric analysis of excised spots from the 2-D
PAGE were performed, and identified proteins with a confi-
dence index 85% and ion score 40 were considered
positive.
RESULTS
Human SP exhibits significant anti-HIV-1 activity
To determine the intrinsic anti-HIV-1 activity of SP, we
assayed whole SP against the R5 strain HIV-1 BaL in
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TZM-bl cells. An R5 phenotype was chosen since it is
primarily responsible for sexually transmitted HIV-1.
After 24 h of infection, the cells were lysed, and
luciferase activity was measured (Fig. 1A; P0.001;
n3). Whole SP revealed significant antiviral activity: at
1% concentration (v/v, 1:100), viral inhibition re-
mained 95%, and SP-1 dilutions 1:100 reduced the
rates of infection in a dose-dependent manner in the
absence of cytotoxicity (Fig. 1B; n3) or adverse effects
on cellular metabolism (Fig. 1C; n3). Because SP
diluted up to 1:3200 retained anti-HIV-1 activity, these
data suggest that the SP component of semen is po-
tently active against HIV-1.
To further validate the anti-HIV activity of SP, the
antiviral activity was confirmed by infecting PM1 cells
with HIV-1 BaL and measuring viral p24 release. Virus
in the presence or absence of vehicle or serial dilutions
of SP was incubated with PM1 cells for 5 d. As com-
pared to a vehicle-only control, the lowest dilution
(1:50) of SP exhibited complete viral inhibition, while
serial dilutions displayed dose-dependent antiviral ac-
tivity (Fig. 2A; P0.0001; n3), in the absence of
appreciable cytotoxicity (Fig. 2B). Taken together,
these results confirm the anti-HIV-1 activity of SP.
Human SP contains numerous cationic polypeptides
We have reported previously that the majority of cat-
ionic polypeptides within human vaginal fluid collec-
tively inhibit HIV-1 infection (6). Herein, we sought
to determine whether human SP contains cationic
polypeptides, whether these polypeptides are similar to
those of human vaginal fluid, and whether the polypep-
tides exert activity against HIV-1. A unique 2-D AU/
tricine-SDS-PAGE approach was utilized to resolve the
cationic polypeptide fraction of SP. Figure 3 reveals a
Sypro Ruby-stained 2-D electropherogram of whole SP
(6.5 l) electrophoresed in an AU-PAGE gel in the first
dimension (horizontal), followed by tricine-SDS-PAGE
in the second dimension (vertical), with each spot
representing an individual polypeptide. Spots were
excised from the gel and digested with trypsin, and 52
individual polypeptides were identified by MALDI-
TOF/TOF MS/MS. The identity of each of the 52
Figure 1. Whole SP inhibits HIV-1 infection. A) TZM-bl cell cultures were treated with serial dilutions of SP or a PBS vehicle
control, and infected with the BaL laboratory strain of HIV-1 (5 ng/ml p24) for 24 h. Inhibition of viral infection was measured
as percentage reduction in luciferase activity (RLU) vs. an infected, vehicle-only control. All dilutions vs. control were
significantly different; P  0.0001. B) Trypan blue assays were performed at 24 h to measure the cytotoxicity of SP and were
expressed as percentage of nonviable cells over total number of cells. C) An MTT assay was also performed in the absence of
infection and measured at 24 h posttreatment. Reduction in cellular metabolic rate was measured as percentage of decreased
tetrazolium production vs. vehicle-only control. Only the 1:10 dilution statistically reduced metabolic activity vs. control; P 
0.0001; n  3. Error bars  sem.
Figure 2. Whole SP inhibits HIV-1 release. A) PM1 cells were
infected with HIV-1 BaL (2 ng/ml p24) in the presence or
absence of serially diluted SP or vehicle-only control. Five days
postinfection, supernatant was collected to quantify p24 re-
lease by ELISA. Data are expressed as percentage inhibition of
infection vs. infected vehicle-only control; P  0.0001 for all
dilutions. B) PM1 cells were subjected to trypan blue assay;
cytotoxicity was expressed as percentage of cells vs. total number
of cells in the infected vehicle-only control. Only the 1:50
dilution was cytotoxic; P  0.05; n  3–6. Error bars  sem.
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polypeptides in Fig. 3 is provided in Table 1. Interest-
ingly, 33 of the spots were found to represent fragments
of 8 parental proteins commonly found in SP, several of
which have putative roles in innate host defense: sem-
enogelin I, semenogelin II, prolactin-induced protein
(PIP), PAP, lactoferrin, prostatic-specific antigen, 	-mi-
croseminoprotein, and cystatin C.
Cationic polypeptides are responsible for the
anti-HIV-1 activity of SP
We utilized a continuous-elution semipreparative AU-
PAGE column gel to isolate each cationic polypeptide
fraction from whole SP for downstream analysis of anti-
HIV-1 activity and cytotoxicity. Forty SP fractions, which
corresponded to the majority of cationic polypeptides
present in Fig. 3, were collected and individually subjected
to tricine-SDS-PAGE. Note that the combination of using
a fractionated AU column gel and tricine-SDS gels is
equivalent to the first and second dimensions, respec-
tively, of the analytical 2-D AU/tricine-SDS-PAGE. Refer-
encing the protein bands in the tricine-SDS gels (Fig. 4A)
to the corresponding spots of a 2-D PAGE electrophero-
gram of SP (Figs. 3 and 4A) afforded the identification of
each protein band.
Each of the 40 SP fractions was subsequently pre-
pared for antiviral assays by undergoing lyophilization
to remove volatile acetic acid, followed by solid-phase
extraction to desalt the samples. Samples were diluted
1:10 in ddH2O and subjected to antiviral assays against
HIV-1 BaL as described above. Fractions 1–10, which
contained polypeptides with the highest cationic charge
density, exhibited the greatest activity against HIV-1 (Fig.
4B; n4) as well as negligible cytotoxicity and reduction
of cellular metabolic activity (Fig. 4C; n4).
SG-1, a 52-residue semenogelin I-derived peptide, is
active against HIV-1
Next, we assessed whether individual cationic polypep-
tides in SP were directly active against HIV-1. The most
abundant, highly cationic protein on Sypro Ruby-stained
2-D PAGE gels (Fig. 3, spot 35) was chosen since the
corresponding fractions, eluted from an AU-PAGE col-
umn gel, exhibited appreciable activity against HIV-1 (Fig.
4B). Fractions 5–9 from an AU-PAGE column gel (Fig.
4A) were pooled and subjected to a 2-step RP-HPLC
purification (Fig. 5). The resulting single-protein band
was visualized (Fig. 6) and sequenced by a combination of
N-terminal Edman peptide sequencing and MALDI-TOF
MS (Fig. 7A). The peptide, termed SG-1, was identified as
a 5750.638-Da peptide whose mass and N-terminal se-
quence (HNKQEGRDHDKSKGH-) corresponded to the
theoretical mass of 5750.837 Da from the 52-aa sequence
NH2-HNKQEGRDHDKSKGHFHRVVIHHKGGKAHRGT
QNPSQDQGNSPSGKGISSQY-COOH, which is a natu-
rally cleaved fragment of the mature 462-aa semenogelin
I polypeptide (9). The SG-1 peptide had been identified
previously as one of several basic proteins in liquefied
SP (20).
To determine whether SG-1 exhibited antiviral activ-
ity, the purified peptide was subjected to anti-HIV-1
assays. SG-1 maintained anti-HIV-1 activity in both a
TZM-bl cell assay (Fig. 7B; n3), and a PM1 cell
antiviral assay (Fig. 7C; n3), and displayed negligible
cytotoxicity (Fig. 7B, C). As the concentration of SG-1
active against HIV-1 in vitro is far less than the estimated
physiological concentration (80 g SG-1/ml whole SP,
data not shown), it is likely that the SG-1 peptide contrib-
utes significantly to the antiviral host defense of SP.
Prolonged incubation of whole SP reduces anti-HIV-1
activity and degrades the majority of semenogelin I
peptides
Since semenogelin-derived peptides continue to de-
grade over time, we wanted to determine whether
proteolytic cleavage affects the anti-HIV-1 activity of
human SP. The SP samples were incubated at timed
intervals at 37°C with constant mild agitation (250
rpm). Incubated SP was tested for antiviral activity in
comparison to whole SP without incubation in a TZM-bl
cell assay (Fig. 8A; n3). SP incubated 24 h retained
significant anti-HIV-1 activity in the absence of cytotoxicity
(Fig. 8B), while incubation intervals 24 h exhibited a
reduction in antiviral activity. These data suggest that the
anti-HIV-1 activity of incubated SP decreases proportion-
ally with increased incubation time.
Postejaculation, the SP coagulum liquefies due to
proteolytic processing; however, this proteolytic cleav-
Figure 3. Resolution and identification of 52 individual
cationic polypeptides in human SP. Whole SP (6.5 l SP-1)
was electrophoresed by AU-PAGE in the first dimension,
followed by a tricine-SDS-PAGE in the second dimension, and
stained with Sypro Ruby. Note that polypeptides with the
highest cationic charge density migrated toward the bottom
right side of the gel. Protein spots were excised and identified
by MALDI-TOF/TOF MS/MS analysis. All labeled spots
(spots 1–52) correspond to proteins described in Table 1.
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age does not cease once the coagulum is liquefied (21).
To determine if the effects of prolonged SP incubation
included degradation of cationic polypeptides, the sam-
ples were subjected to AU-PAGE (Fig. 9A), and tricine-
SDS-PAGE (Fig. 9C). Protein-band patterns visibly
changed at 6 h of incubation and progressively dis-
persed into protein bands with higher cationic charges
and smaller molecular mass. To track the effects of
prolonged incubation on the antimicrobial semenoge-
lin I proteins, samples were subjected to Western blot
analysis (Fig. 9B, D) with an antisemenogelin I poly-
clonal antibody. It has been shown that semenogelins
are degraded selectively over time (14). The effects of
incubation on semenogelin I proteins were visible after
TABLE 1. Identified cationic polypeptides from 2-D PAGE and MALDI-TOF/TOF MS/MS analysis
Spot Spot ID Accession
Spot mass
(kDa) Ion score CI (%)
Protein mass
(kDa)
1 Prolactin-induced protein gi 4505821 20 312 100 16.56
2 Semenogelin I gi 37731930 20 18 99.46 10.38
3 Prolactin-induced protein gi 4505821 19 148 100 16.56
4 Prolactin-induced protein gi 4505821 19 0 99.35 16.56
5 Ig heavy-chain V region gi 346162 18.5 64 99.69 13.15
6 Prolactin-induced protein/PSA gi 4505821/gi 14250150 18 277/42 100/99.8 16.56/44.48
7 Keratin 1, type II, cytoskeleton gi 7428712 17 320 100 65.45
8 PAP/prolactin induced protein gi 27574174/gi 4505821 16.5 154/86 100/100 40.97/16.56
9 Semenogelin II gi 47683071 17 0 99.94 65.43
10 Semenogelin I preproprotein gi 33392699 17 25 99.55 45.26
11 Lactoferrin gi 386855 15 53 99.58 30.56
12 Lactoferrin gi 386855 15 67 99.99 30.56
13 Cystatin C precursor/semenogelin II gi 15341822/gi 32699322 16 135/62 100/99.9 15.78/65.43
14 Keratin 1, type II, cytoskeleton gi 7331218 14.3 279 100 65.97
15 Microseminoprotein 	 gi 225159 14.5 91 100 10.64
16 Prolactin-induced protein gi 4505821 14 196 100 16.56
17 Semenogelin II gi 4506885 13 62 99.979 65.4
18 Bullous pemphigoid antigen gi 27923959 14 70 99.92 371.9
19 Protein product of HMFN1661 gi 51555816 12 46 82.09 19.68
20 Keratin 10 gi 623409 12 56 99.72 57.21
21 Semenogelin II precursor gi 47683071 10 76 100 65.43
22 Prostatic acid phosphatase gi 6137673 9 58 99.66 39.7
23 Hypothetical protein gi 21732890 10 61 99.37 196.9
24 Prostatic acid phosphatase gi 16740983 8.5 42 98.037 44.51
25 Semenogelin I preproprotein gi 38049014 9 207 100 45.27
26 Semenogelin I gi 32450803 8 30 99.836 45.29
27 Semenogelin I preproprotein gi 32450803 8.5 117 100 45.29
28 ATP synthase, H transporting,
mitochondrial
gi 12654679 8 55 97.97 12.58
29 Prostatic acid phosphatase gi 515997 7 74 99.99 44.53
30 Semenogelin I preproprotein gi 38049014 7.5 115 100 45.27
31 Semenogelin I gi 37728854 7 85 100 23.79
32 Semenogelin I gi 33392699 6 47 99.65 45.26
33 Semenogelin I preproprotein gi 32450803 6 58 99.99 45.29
34 DAP-2 gi 89028478 5 40 26.15 9.169
35 Semenogelin I gi 37728828 5–8 12 99.49 19.92
36 Clusterin gi 42716297 5 108 100 57.79
37 Semenogelin I gi 32450803 5 80 100 45.29
38 FLJ00150 protein gi 18676506 4.75 49 90.04 207.2
39 Microtubule-actin crosslinking factor gi 55665463 4.5 44 73.18 505.3
40 Semenogelin I gi 37728854 4 41 81.02 23.79
41 SHQ1 homolog gi 34193077 4 51 93.85 65.11
42 Intercellular adhesion molecule gi 85068578 4 48 89.45 29.63
43 Semenogelin II gi 4506885 3.5 44 97.82 65.4
44 NPD003 gi 5531825 3.5 41 41.34 33.31
45 Semenogelin I preproprotein gi 37728854 3 54 99.28 23.79
46 Semenogelin I preproprotein gi 38049014 2.8 80 100 45.27
47 Semenogelin I gi 37728854 3 74 99.99 23.79
48 RQCD1 protein gi 13937977 3 45 77.7 29.11
49 Semenogelin II gi 32699322 2.8 67 100 65.43
50 HSPC337 gi 6841324 2.8 53 96.12 20.39
51 Microtubule-actin crosslinking factor gi 55665463 2.75 49 90.48 505.3
52 Growth differentiation factor 2 gi 7705308 2 40 17.14 47.29
Table identifies spots shown in Fig. 3. CI, confidence index.
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6 h, exhibiting an increasingly degraded protein-band
pattern in samples incubated for 24 h or longer. These
data suggest that the decreased anti-HIV-1 activity of
incubated SP is correlated directly with the increased
degradation of semenogelin I proteins. Due to the
abundance of semenogelin-derived peptides in com-
parison to other identified peptides observed in our
study (Table 1), and the activity exhibited by semeno-
gelin-derived peptides, this study confirms the impor-
tance of semenogelins to the intrinsic antiviral activity
of SP.
Figure 4. Cationic polypeptide fractions of SP exhibit significant anti-HIV-1
activity. A) After column-gel AU-fractionation of whole SP, 40 fractions were
collected and electrophoresed on mini-tricine-SDS gels. Silver staining re-
vealed peptide bands retained in each individual fraction. To reference
fractions to the corresponding spots previously identified by 2-D PAGE, the
2-D Sypro Ruby-stained gel image was inverted and displayed as a negative digital effect, and flipped in the horizontal axis
as compared with Fig. 1. In this orientation, the most cationic polypeptides are to the left of the gel. B) Cells were treated
in a TZM-bl antiviral assay with the fractionated SP (fractions 1–40) at a dilution of 1:10. Fractions 5–9 were most active and
contained the identified semenogelin I peptide termed SG-1 (Fig. 1, spot 35). C) An MTT assay conducted in parallel to
the antiviral assay measured metabolic reduction as percentage reduction of the medium-only negative control; n 4. Error
bars  sem.
Figure 5. Purification of SG-1 by analytical and microbore
RP-HPLC. SG-1 was purified by a 2-step RP-HPLC, with
fractionation using the organic solvent ACN and 0.08% TFA
as an ion-pairing agent. Solvent gradient is shown as a
percentage (dotted line); eluted peptides are represented as
intensity of the total ion current (TIC; solid line). A) Analyt-
ical column was loaded with the fractionated SP-1 pool (Fig.
4, fractions 5–9). B) Semipure peak fraction representing
SG-1 was loaded onto a microbore column, and SG-1 was
eluted at 17.25% of the ACN solvent.
Figure 6. Stepwise purification of the SG-1 peptide. Purifica-
tion of SG-1 from whole SP to isolated pure peptide was
represented by electrophoresing samples from each step of
purification on a mini-tricine-SDS gel. A 1:100 dilution of SP,
a sample of fractionated SP (pooled fractions 5–9), a sample
of the semipurified SG-1 from analytical RP-HPLC, and the
purified SG-1 from the microbore RP-HPLC column (4 l
each) were visualized with Coomassie blue (A) and silver
staining (B). Native SG-1 was utilized in the remaining assays.
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DISCUSSION
Mucosal secretions are thought to play a fundamental
role in host defense, due in large part to intrinsic
antimicrobial peptides and proteins elaborated in the
fluid. In the current study, we revealed that SP exhib-
ited significant anti-HIV-1 activity and that the activity
resided mainly in the cationic polypeptide fraction.
Furthermore, polypeptide fractions with greater cat-
ionic charge density demonstrated increased anti-
HIV-1 activity as compared to less cationic polypeptide
fractions, suggesting that charge was an essential deter-
minant of antiviral activity. On prolonged incubation of
SP, antiviral activity decreased concomitant with the
degradation of semenogelin I peptides, further empha-
sizing the role of cationic antimicrobial polypeptides in
anti-HIV-1 host defense. While our study is the first to
associate the majority of cationic polypeptides found in
human SP with the fluid’s intrinsic anti-HIV-1 activity,
this finding was not altogether surprising: The vast
majority of polypeptides with reported activity against
microbes and viruses are cationic in nature (22).
Figure 7. SG-1 peptide is naturally active against HIV-1. SG-1 was sequenced and identified by Edman degradation and mass
spectrometric analysis. A) Mature semenogelin I, lacking the 23-residue signal peptide sequence; the 52-aa SG-1 sequence is
identified. B) A TZM-bl antiviral assay against HIV-1 BaL (5 ng/ml p24) was performed with the natural SG-1 peptide (5 g/ml).
Inhibition of viral infection was measured as percentage reduction in luciferase activity vs. vehicle-only control. A trypan blue
assay was performed in parallel to measure cytotoxicity, expressed as percentage of nonviable cells vs. total cells. C) PM1 cells
were infected with HIV-1 BaL (2 ng/ml p24) in the presence or absence of natural SG-1 peptide (15 g/ml) or vehicle-only
control. Supernatant was collected 5 d postinfection to quantify p24 release by ELISA. Data are expressed as percentage
inhibition of infection vs. infected vehicle-only control. On d 5, postinfection PM1 cells were subjected to trypan blue assay;
cytotoxicity was expressed as percentage of cells vs. total cells in the infected vehicle-only control; n  3. Error bars  sem.
Figure 8. Incubation of whole SP affects anti-HIV-1 activity.
A) TZM-bl cells were treated with 1:100 dilutions of whole SP
incubated for timed intervals or a PBS vehicle control (0, 6,
and 12 h, and 1, 2, 3, 4, and 5 d at 37°C, with gentle agitation;
250 rpm). Cells were infected with HIV-1 BaL (5 ng/ml p24)
for 24 h. Inhibition of viral infection was measured as
percentage reduction in luciferase activity vs. infected vehicle-
only control. All SP samples were significantly higher in
activity vs. control; P  0.0001. B) MTT assays were also
performed, in the absence of infection, and measured at 24 h
posttreatment. Reduction in cellular metabolic activity was
measured as percentage of decreased tetrazolium production
vs. vehicle-only control. No dilution statistically reduced met-
abolic activity vs. control; n  3. Error bars  sem.
Figure 9. Prolonged incubation of SP results in increasingly
degraded semenogelin I. Incubated SP samples (1 l/lane)
were electrophoresed on minipolyacrylamide gels. Samples
were electrophoresed on 12.5% mini-AU gels and stained
with Sypro Ruby protein stain (A) or Western blotting with a
polyclonal anti-semenogelin I antibody(B). Degradation of
cationic semenogelin I peptides was evident with prolonged
incubation time. SP samples were also electrophoresed on
16% mini-tricine-SDS gel and stained with Sypro Ruby pro-
tein stain (C) or Western blotting with the anti-semenogelin I
antibody (D). A similar pattern of peptide degradation was
shown with prolonged incubation.
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The 2-D AU/tricine-SDS-PAGE system was chosen for
its unique ability to separate cationic polypeptides.
Indeed, we have utilized this technique to identify
cationic polypeptides that contribute to the antimicro-
bial and antiviral host defenses of human nasal fluid
and vaginal fluids (6, 23). In the current study, 33 of
the identified polypeptides were relevant to host de-
fense. Many polypeptides were cleavage products of
semenogelin I and semenogelin II, the most abundant
proteins in SP (10, 24, 25), both of which have been
reported to exhibit antibacterial activity (13, 14). In
addition, the protease PAP is involved in the processing
and degradation of semenogelins and likely plays an
important role during postcoital coagulum processing
to liberate active anti-HIV-1 peptides (26). The seminal
vesicle-derived PIP, also known as gp17 glycoprotein, is
a high-affinity CD4 ligand that has been shown to
inhibit HIV-1 gp120-mediated syncytium formation
(27). Lactoferrin, a broad-spectrum antimicrobial pro-
tein, can prevent the early stages of HIV-1 infection by
preventing the virus from entering host cells (28–31).
	-Microseminoprotein is one of the predominant pro-
teins secreted from the prostate, and while no definitive
biological functions are ascribed to this protein, it has
been shown to decrease tumor growth in the prostate
and has purported roles in host defense (32, 33). The
cysteine proteinase inhibitor cystatin C reportedly pre-
vents viral replication of HSV and coronaviruses (34–
36). Collectively, the identity and function of these
polypeptides strongly suggest a function for SP in
antiviral host defense. As most of these polypeptides are
not components of vaginal fluid, it remains to be
determined whether the antiviral polypeptides from SP
work in concert with polypeptides from vaginal fluid to
prevent sexual transmission of HIV-1.
SP is a complex biological fluid, containing both
antiviral and proviral factors (37). Notably, a recent
study revealed that naturally occurring PAP fragments
in semen form amyloid fibrils that enhance HIV-1
infection by capturing virions and promoting attach-
ment to target cells (15). Several differences between
their approach and our current study might explain
these contrasting findings. Methodological differences
in our study include the initial liquefaction of SP, the
use of FBS in HIV-1 infection assays, and extended
incubation of target cells with SP. While their study
defends the washing of cell monolayers after 3 h due to
concerns of cytotoxicity, our study suggests that at the
low concentrations of SP needed to observe antiviral
activity (2% v/v of SP) cellular metabolism was nor-
mal and insignificant cytotoxicity was observed. Our
2-D analysis displayed PAP fragments at 16.5 kDa, but
we did not observe any at the designated 4- to 4.5-kDa
range previously published as HIV enhancers. While
these differences prevent a truly paralleled comparison,
both studies should be taken together as they suggest
that proviral and antiviral forces may be in direct
competition in SP in vivo. In fact, we have also shown
that vaginal fluid elaborates components (e.g., cal-
granulin A) that are permissive for viral infection (6).
Whether the relative concentrations of proviral and
antiviral components in an individual’s seminal or
vaginal fluid are predictive of susceptibility to HIV-1
infection is a subject that warrants further investigation.
Our study demonstrated that human SP exhibits signif-
icant intrinsic anti-HIV-1 activity and characterized a cat-
ionic polypeptide, SG-1, as an anti-HIV-1 component of
SP. Future studies, which we are actively pursuing, will
further analyze the mode of viral inhibition SG-1 uses.
While previously established as antibacterial, no other
studies have determined that semenogelins exhibit signif-
icant antiviral activity. These findings set the stage for
future studies to determine the host defense role of the
myriad other cationic polypeptides we identified in SP.
The presence of such an anti-HIV-1 mechanism in SP may
be one reason why the chance of infection is so low (3
in 1000 coital acts) in healthy populations (38).
We thank the laboratory staff at the Center for Reproduc-
tive Medicine (Orlando, FL, USA) for their expert technical
assistance.
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